PharmiWeb.com - Global Pharma News & Resources
10-Oct-2022

New Preclinical Data on CNS Programs to be presented at European Society of Gene & Cell Therapy Congress 2022 and International Symposium on NBIA

London, UK, 10 October 2022 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, today announced that pre-clinical data from two of its brain-targeted programs, BGT-INAD and BGT-DTDS, will be featured respectively in an oral presentation and a poster at the upcoming European Society of Gene & Cell Therapy (“ESGCT”) Congress 2022 to be held on 11-14 October 2022 in Edinburgh, Scotland. In addition, the Company’s founding scientists, Professor Manju Kurian and Professor Ahad Rahim, will be presenting pre-clinical data from BGT-INAD and infantile neuroaxonal disease (“INAD”)  in oral presentations at the upcoming 8th International Symposium on NBIA to be held on 13-15 October 2022 in Lausanne, Switzerland.

 

ESGCT Oral presentation Details

 

Presentation Title: AAV9-mediated gene therapy in a knock-in mouse model of infantile neuroaxonal dystrophy

Presentation Number: OR30

Session: Parallel 3a – CNS and sensory diseases I

Presenting Author: Dr Amy Geard, UCL London

 

ESGCT Poster Presentation Details:

 

Presentation Title: Long term correction of Dopamine transporter deficiency syndrome following midbrain gene therapy

Presentation Number: P224

Presenting Author: Dr Joanne Ng, UCL EGA Institute for Women’s Health

 

International Symposium on NBIA Presentation Details:

 

Presentation Title: Towards precision therapies for NBIA

Session: Session 5, PLAN/INAD & FAHN

Presenting Author: Professor Manju Kurian, UCL

 

Presentation Title: PLA2G6-associated neurodegeneration - update

Session: Session 5, PLAN/INAD & FAHN

Presenting Author: Professor Manju Kurian, UCL

 

Presentation Title: Developing gene therapy for PLAN and moving towards clinical trials

Session: Session 5, PLAN/INAD & FAHN

Presenting Author: Professor Ahad Rahim, UCL

Editor Details

Related Links

Last Updated: 10-Oct-2022